First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in Caucasian patients (pts) (NCT00339586)-FIELT study group.

被引：2

作者：

De Greve, J.

Van Meerbeeck, J. P.

Vansteenkiste, J. F.

Teugels, E.

Geers, C.

Meert, A.

Vuylsteke, P.

Focan, C. N. J.

Canon, J.

Humblet, Y.

Berchem, G. J.

Colinet, B.

Galdermans, D.

Bosquee, L.

Dooms, C. A.

Decoster, L.

Vermeij, J.

Dewaele, A.

Schallier, D. C. C.

机构：

[1] Univ Ziekenhuis Brussels, Brussels, Belgium

[2] Ghent Univ Hosp, Ghent, Belgium

[3] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

[4] UZ Brussel, Brussels, Belgium

[5] Inst Jules Bordet, B-1000 Brussels, Belgium

[6] Clin & Maternite Sante Elisabeth, Namur, Belgium

[7] CHC Clin St Joseph, Liege, Belgium

[8] Grand Hop Charleroi, Charleroi, Belgium

[9] Catholic Univ Louvain, Ctr Canc, B-1200 Brussels, Belgium

[10] Ctr Hospier Luxembourg, Luxembourg, Luxembourg

[11] AZ Middelheim Hosp, Antwerp, Belgium

[12] CHU Sart Tilman, Dept Resp Med, B-4000 Liege, Belgium

[13] Univ Hosp Leuven, Leuven, Belgium

[14] Univ Ziekenhuis Brussels, Dept Med Oncol, Oncol Ctr, Brussels, Belgium

[15] ZNA Campus Jan Palfijn Middelheim, Merksem, Belgium

[16] Univ Ziekenhuis Brussels, Jette, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.7597

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7597

引用

页数：1